The role of OncoSnoRNAs and Ribosomal RNA 2'-O-methylation in Cancer. (15th October 2021)

• Record Type: Journal Article
• Authors: Barros-Silva, Daniela; Klavert, Jonathan; Jenster, Guido; Jerónimo, Carmen; Lafontaine, Denis L.J.; Martens-Uzunova, Elena S.
• Is Part Of: RNA biology. Volume 18(2021)Supplement 1
• Page Start: 61
• Page End: 74
• Publication Date: 2021-10-15
• Subjects: Ribosome -- ribosomal RNA 2'-O-methylation -- box C/D snoRNA -- Fibrillarin -- cancer biomarker -- cancer diagnostics -- cancer prognostics -- cancer therapeutics; RNA -- Periodicals; Molecular biology -- Periodicals; Molecular biology; RNA; Periodicals; 572.8805
• DOI: 10.1080/15476286.2021.1991167
• Languages: English
• ISSNs: 1547-6286

Abstract

ABSTRACT: Ribosomes are essential nanomachines responsible for all protein production in cells. Ribosome biogenesis and function are energy costly processes, they are tightly regulated to match cellular needs. In cancer, major pathways that control ribosome biogenesis and function are often deregulated to ensure cell survival and to accommodate the continuous proliferation of tumour cells. Ribosomal RNAs (rRNAs) are abundantly modified with 2'-O-methylation (Nm, ribomethylation) being one of the most common modifications. In eukaryotic ribosomes, ribomethylation is performed by the methyltransferase Fibrillarin guided by box C/D small nucleolar RNAs (snoRNAs). Accumulating evidences indicate that snoRNA expression and ribosome methylation profiles are altered in cancer. Here we review our current knowledge on differential snoRNA expression and rRNA 2ʹ-O methylation in the context of human malignancies, and discuss the consequences and opportunities for cancer diagnostics, prognostics, and therapeutics.